<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>


Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  

March 29, 2017
9:15am - 9:45am EDT

Trovagene's chief executive officer, Bill Welch, will present at the Sidoti & Company Spring Convention at the Marriott Marquis in New York Citty on March 29th at 9:15 AM EDT. The presentation...

email print
Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593

E-mail    ir@trovagene.com